Navigation Links
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
Date:3/16/2009

DUBLIN, March 16 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has decided to withdraw the European Marketing Authorization Application (MAA) for DAYTRANA(TM) (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). A request from European regulators to conduct an additional clinical study on DAYTRANA in a European patient population combined with the recently announced planned acquisition of the worldwide rights (excluding the US, Canada and Barbados) to EQUASYM(R) IR and XL (methylphenidate hydrochloride) for the treatment of ADHD are the basis for this decision.

The decision to withdraw the MAA does not impact Shire's commitment to DAYTRANA in the U.S. where the product has been used as a pediatric treatment for ADHD since 2006.

EQUASYM IR and XL will provide Shire with an entry to the European ADHD market upon completion of the transaction, which subject to customary completion conditions, is anticipated in Q2 2009. EQUASYM XL is approved and currently marketed for the treatment of ADHD in children over 6 years of age, and is available in 10 countries outside of the US, Canada and Barbados including Denmark, Finland, Germany, Ireland, Netherlands, Norway, Sweden, UK, Mexico and South Korea. Shire will be working to progress a number of additional planned launches for EQUASYM XL in European and ROW markets.

EQUASYM will allow Shire to build on its status as the leader in the United States ADHD market with patients and customers in Europe, and establishes a solid bridge for Shire's other ADHD treatments, including VYVANSE(TM) (lisdexamfetamine dimesylate), its flagship ADHD product, in territories outside of the United States. VYVANSE is approved in the US for the
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
10. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
11. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  BC Technical, the ... MiE America , Inc., a leading provider of ... into a long-term agreement naming BC Technical as the ... MiE and BC Technical announced today ... to establish BC Technical as the service and systems ...
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
(Date:7/10/2014)... CAESAREA, Israel , July 10, 2014 /PRNewswire/ ... Dario™ Diabetes Management Solution, today announced the appointment ... an independent member of its Board of Directors. ... of legal and business experience to LabStyle as ... director, and legal and corporate governance expert. He ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... Genesis Biopharma, Inc. (OTC Bulletin Board: ... therapies, announces that CEO Robert Brooke will present a company ... 12, 2011, at 9:45 a.m. Pacific time.  The conference is ... Union Square. "We look forward to discussing our ...
... The pharmaceutical industry,s steep patent cliff and ... executives to uncover opportunities for sustainable growth in ... branded products to extend patent life. For pharma ... a therapeutic advantage and become part of lifecycle ...
Cached Medicine Technology:Genesis Biopharma to Present at 2011 Biotech Showcase Conference 2Report Highlights Successful Strategies for Bringing FDC Products to Market 2
(Date:7/12/2014)... 12, 2014 The rise in the ... for new advanced network architectures to suit the upsurge. ... industry with increasing cloud storage technologies. The data traffic ... more mobility devices. This has resulted in larger and ... driving forces for the SDN market. , The North ...
(Date:7/12/2014)... 2014 Demand Response Management Systems is ... in reducing the imbalance between energy supply and demand. ... been rolled out (due to increasing pressure on the ... helps in controlling residential appliances and thermostats for load ... North American region, and with government mandates and benefits ...
(Date:7/12/2014)... (HealthDay News) -- If you make exercise fun, you,ll eat ... experiment, 56 adults were led on a 1.4-mile walk and ... a scenic walk. The participants were given lunch after the ... outing ate 35 percent more chocolate pudding for dessert than ... In another experiment, 46 adults were given mid-afternoon snacks after ...
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 Using ... so one of two inventors from Ashland, Va., decided ... do this. "This inspired us to conceive of our ... of the patent-pending KIDNEY KOVER, which provides an inconspicuous ... It avoids embarrassment, as well as promotes comfort and ...
(Date:7/12/2014)... “Critical Care Therapeutics in Major Developed ... PCCs and Recombinant Products to Drive Market,” which ... in the US, UK, France, Germany, Italy, Spain, ... of market size for 2013, along with market ... that are being treated using the five major ...
Breaking Medicine News(10 mins):Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 5Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6
... ban production of low-grade plastic from Wednesday, Chief Minister ... the World Environment Day. ,Bhattacharya urged the ... their assistance in formulating an environment-friendly policy. ... plastic production (below 40 micron) in West Bengal. Earlier ...
... have slightly higher survival rates when treated with the ... according to a study in the June 6 Journal ... cisplatin chemotherapy should remain the standard of care for ... prefer carboplatin to cisplatin because it has fewer side ...
... fifteen months after the 9/11 terrorist attacks, President George W. ... Executive Office Building next door to the White House ... laboratories, and we believe that regimes hostile to the United ... that a smallpox attack is imminent. Yet it is prudent ...
... They live longer than almost anyone in the region. Far ... scourges of the poor as parasites, TB, malaria, even ... at low cost, right in the neighborhood. ,The success ... recent Michael Moore documentary pouring scorn on healthcare in US ...
... disorder (BPD) can be reduced by an intensive ... (TFP) thereby reducing the symptoms and improving their social ... of the American Journal of Psychiatry, a premier psychiatry ... affecting about 1% of the United States population, has ...
... by bird flu, have found preliminary evidence which suggests ... warned Wednesday . ,The head of Indonesia's ... told reporters the human fatality rate had increased in ... with 74.5 percent the previous year. ,Krisnamurthi ...
Cached Medicine News:Health News:New Smallpox Vaccine Contract: Five Years in the Making 2Health News:Cuba is Exporting Healthcare Now 2Health News:Cuba is Exporting Healthcare Now 3Health News:Cuba is Exporting Healthcare Now 4Health News:Cuba is Exporting Healthcare Now 5Health News:Intensive Psychotherapy Provides Helping Hand in Borderline Personality Disorder. 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: